Study of S-1 for Lung Cancer
Author Information
Author(s): Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H
Primary Institution: National Kinki Central Hospital for Chest Diseases, Osaka
Hypothesis
The study aimed to evaluate the efficacy and safety of S-1 in patients with advanced non-small-cell lung cancer.
Conclusion
S-1 was found to be an active treatment for advanced non-small-cell lung cancer, with manageable side effects.
Supporting Evidence
- The partial response rate was 22.0% among eligible patients.
- The median response duration was 3.4 months.
- The median survival time was 10.2 months.
- The one-year survival rate was 41.1%.
Takeaway
This study tested a new medicine called S-1 to see if it helps people with a type of lung cancer, and it seems to work pretty well.
Methodology
Patients received S-1 orally, twice daily, for 28 days followed by a 2-week rest, with up to 4 cycles.
Limitations
The study had a small sample size and was limited to patients who had not received previous chemotherapy.
Participant Demographics
59 patients were evaluated, including 22 stage IIIB and 37 stage IV.
Statistical Information
Confidence Interval
95% confidence interval: 12.3–34.7% for partial response rate; 95% confidence interval: 7.7–14.5 months for median survival time.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website